Back to Journals » Cancer Management and Research » Volume 9

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape

Authors Subramanian J, Cavenagh J, Desai B, Jacobs I

Received 25 August 2016

Accepted for publication 5 January 2017

Published 24 April 2017 Volume 2017:9 Pages 131—140

DOI https://doi.org/10.2147/CMAR.S120589

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Kexin Xu

Janakiraman Subramanian,1 Jamie Cavenagh,2 Bhardwaj Desai,3 Ira Jacobs4

1Division of Medical Oncology, Saint Luke’s Cancer Institute, Kansas City, MO, USA; 2Department of Haematology, St. Bartholomew’s Hospital, London, UK; 3Prospect Heights, IL, 4Global Established Pharma, Pfizer Inc., New York, NY, USA

Abstract: Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. FL is an incurable disease with treatment options ranging from a “watch-and-wait” approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development. Despite the prospect of new agents on the horizon, it is widely accepted that rituximab will remain as the cornerstone of therapy because of its established long-term efficacy. Many biologics, including rituximab, have lost exclusivity of composition-of-matter patent or will do so in the next few years, which is a concern for patients and physicians alike. Moreover, access to rituximab is challenging, particularly in countries with restricted resources. Together, these concerns have fueled the development of safe and effective biosimilars. The term “biosimilar” refers to a biologic product that is highly similar to an approved reference (or originator) product, notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences in purity, potency, or safety. Biosimilars are developed to treat the same condition(s) using the same treatment regimens as an approved reference biologic, and have the potential to increase access to more affordable treatment of FL. Herein, we also discuss the potential benefits of eagerly awaited rituximab biosimilars, which may mitigate the impact of the lack of access to rituximab.

Keywords: biosimilar, follicular lymphoma, non-Hodgkin’s lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Drug tendering: drug supply and shortage implications for the uptake of biosimilars

Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG

ClinicoEconomics and Outcomes Research 2017, 9:573-584

Published Date: 29 September 2017

Can biosimilars help achieve the goals of US health care reform?

Boccia R, Jacobs I, Popovian R, de Lima Lopes Jr G

Cancer Management and Research 2017, 9:197-205

Published Date: 1 June 2017

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

Jacobs I, Singh E, Sewell KL, AL-Sabbagh A, Shane LG

Patient Preference and Adherence 2016, 10:937-948

Published Date: 26 May 2016